Polymorphism of Secretary PLA2G2A Gene Associated with Its Serum Level in Type2 Diabetes Mellitus Patients in Northern Iran
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Inflammation may occur in Type2 diabetes mellitus. sPLA2 is among the factors that contribute to the activation of pathways involved in inflammation. Several agents affect serum sPLA2 level, one of which is genetic diversity.
OBJECTIVE: The current study was performed to determine whether there is a relationship between sPLA2 gene (-763C > G) polymorphism and circulating sPLA2 level in patients with Type 2 diabetes.
METHODS: DNA was extracted from blood samples and used for the amplification of sPLA2 gene using ARMS-PCR.
RESULTS: A statistical analysis using SPSS (version 16) revealed a significant correlation between -763C > G sPLA2 gene polymorphisms and the disease incidence in patients with T2DM. Among the three possible genotypes (GG, CC, and CG), CG genotype was found to have a higher frequency(53%) in T2DM patients. GG and CC genotypes frequencies were 20 and 27%, respectively. In healthy individuals, the frequencies of CC, GG, and GC genotypes were 77, 9.8% and 13.2%, respectively). Patients with genotype GG had the highest level of sPLA2. We showed that C>G polymorphism at position- 763 is associated with a high level of sPLA2 in both T2DM patients and healthy individuals. The average of sPLA2 circulating level was (170.48± 84.90), (106.62 ± 74.31), in patients and normal individuals, respectively.
CONCLUSION: Our findings show that sPLA2 serum level is significantly higher in patients with T2DM disease than that in healthy individuals.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Endocrine, metabolic & immune disorders drug targets - 19(2019), 8 vom: 30., Seite 1192-1197 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khajeniazi, Safoura [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.04.2020 Date Revised 20.04.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1871530319666190528111225 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM297510665 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM297510665 | ||
| 003 | DE-627 | ||
| 005 | 20231225092141.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871530319666190528111225 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0991.xml |
| 035 | |a (DE-627)NLM297510665 | ||
| 035 | |a (NLM)31132981 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khajeniazi, Safoura |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Polymorphism of Secretary PLA2G2A Gene Associated with Its Serum Level in Type2 Diabetes Mellitus Patients in Northern Iran |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.04.2020 | ||
| 500 | |a Date Revised 20.04.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Inflammation may occur in Type2 diabetes mellitus. sPLA2 is among the factors that contribute to the activation of pathways involved in inflammation. Several agents affect serum sPLA2 level, one of which is genetic diversity | ||
| 520 | |a OBJECTIVE: The current study was performed to determine whether there is a relationship between sPLA2 gene (-763C > G) polymorphism and circulating sPLA2 level in patients with Type 2 diabetes | ||
| 520 | |a METHODS: DNA was extracted from blood samples and used for the amplification of sPLA2 gene using ARMS-PCR | ||
| 520 | |a RESULTS: A statistical analysis using SPSS (version 16) revealed a significant correlation between -763C > G sPLA2 gene polymorphisms and the disease incidence in patients with T2DM. Among the three possible genotypes (GG, CC, and CG), CG genotype was found to have a higher frequency(53%) in T2DM patients. GG and CC genotypes frequencies were 20 and 27%, respectively. In healthy individuals, the frequencies of CC, GG, and GC genotypes were 77, 9.8% and 13.2%, respectively). Patients with genotype GG had the highest level of sPLA2. We showed that C>G polymorphism at position- 763 is associated with a high level of sPLA2 in both T2DM patients and healthy individuals. The average of sPLA2 circulating level was (170.48± 84.90), (106.62 ± 74.31), in patients and normal individuals, respectively | ||
| 520 | |a CONCLUSION: Our findings show that sPLA2 serum level is significantly higher in patients with T2DM disease than that in healthy individuals | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ARMSPCR | |
| 650 | 4 | |a Secretary phospholipase A2 | |
| 650 | 4 | |a gene expression | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a polymorphism | |
| 650 | 4 | |a type 2 diabetes mellitus. | |
| 650 | 7 | |a Inflammation Mediators |2 NLM | |
| 650 | 7 | |a Group II Phospholipases A2 |2 NLM | |
| 650 | 7 | |a EC 3.1.1.4 |2 NLM | |
| 650 | 7 | |a PLA2G2A protein, human |2 NLM | |
| 650 | 7 | |a EC 3.1.1.4 |2 NLM | |
| 700 | 1 | |a Marjani, Abdoljalal |e verfasserin |4 aut | |
| 700 | 1 | |a Shakeri, Raheleh |e verfasserin |4 aut | |
| 700 | 1 | |a Hakimi, Safoura |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Endocrine, metabolic & immune disorders drug targets |d 2006 |g 19(2019), 8 vom: 30., Seite 1192-1197 |w (DE-627)NLM161976174 |x 2212-3873 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2019 |g number:8 |g day:30 |g pages:1192-1197 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871530319666190528111225 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2019 |e 8 |b 30 |h 1192-1197 | ||